Risk stratifying asymptomatic left ventricular systolic dysfunction in the community: beyond left ventricular ejection fraction.


Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 01 08 2019
accepted: 26 11 2019
pubmed: 7 12 2019
medline: 29 6 2021
entrez: 7 12 2019
Statut: ppublish

Résumé

Midwall fractional shortening (MWFS) is a measure of left ventricular (LV) systolic function that is more reliable in case of concentric LV geometry compared to LV ejection fraction (LVEF). We hypothesized that MWFS might predict heart failure (HF) and death in a high-risk asymptomatic population, beyond other echocardiographic parameters. Among 4047 subjects aged ≥55/≤80 years followed by 10 general practitioners in northern Italy, the DAVID-Berg study prospectively enrolled 623 asymptomatic outpatients at increased risk for HF. Baseline evaluation included clinical visit, electrocardiogram, N-terminal pro-brain natriuretic peptide (NT-proBNP), and echocardiogram. Mean age of the population was 69 ± 7 years, 56% were men, 88% had hypertension, mean LVEF was 61 ± 9%, and mean MWFS 16.2 ± 3.3. During a median follow-up of 5.7 years, 95 subjects experienced HF/death events. At Cox analysis, lower MWFS was the only echocardiographic parameter, among structural/functional ones, associated with higher risk of HF/death [hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.84-0.95, Padjusted < 0.001]. The risk of HF/death related to clinical data and NT-proBNP (baseline model) was reclassified by echocardiography only when MWFS was included into the model (baseline C-statistics 0.761; adding conventional structural/functional echocardiographic data 0.776, P = 0.09; adding MWFS 0.791, P = 0.007). Compared to subjects with normal LVEF and MWFS, only subjects with combined systolic dysfunction (11% of the population) were at higher risk (P = 0.001 for both abnormal; P > 0.24 for either LVEF or MWFS abnormal). DAVID-Berg data suggest to include MWFS assessment in clinical practice, a simple and reliable echocardiographic parameter able to improve risk stratification in subjects at high risk for HF.

Identifiants

pubmed: 31808506
pii: 5662404
doi: 10.1093/ehjci/jez298
doi:

Substances chimiques

Biomarkers 0
Peptide Fragments 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1405-1411

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Auteurs

Simone Burocchi (S)

CardioVascular Department, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1, Bergamo, Italy.
Division of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital University of Rome Sapienza, Via di Grottarossa, 00189 Roma, Italy.

Mauro Gori (M)

CardioVascular Department, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1, Bergamo, Italy.

Giovanni Cioffi (G)

Division of Rheumatology, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale Aristide Stefani, 1, Verona, Italy.

Alice Calabrese (A)

CardioVascular Department, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1, Bergamo, Italy.

Paolo Canova (P)

CardioVascular Department, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1, Bergamo, Italy.

Renata De Maria (R)

CNR Institute of Clinical Physiology, CardioThoracic and Vascular Department, Niguarda Ca' Granda Hospital, Piazza dell'Ospedale Maggiore, 3, Milano, Italy.

Aurelia Grosu (A)

CardioVascular Department, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1, Bergamo, Italy.

Alessandra Fontana (A)

CardioVascular Department, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1, Bergamo, Italy.

Attilio Iacovoni (A)

CardioVascular Department, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1, Bergamo, Italy.

Paola Ferrari (P)

CardioVascular Department, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1, Bergamo, Italy.

Massimo Volpe (M)

Division of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital University of Rome Sapienza, Via di Grottarossa, 00189 Roma, Italy.
IRCCS Neuromed, Loc. Camerelle, Pozzilli IS, Italy.

Luciano De Biase (L)

Division of Cardiology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital University of Rome Sapienza, Via di Grottarossa, 00189 Roma, Italy.

Gianfranco Parati (G)

Department of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano, IRCCS, S. Luca Hospital, Milan, Italy, Department of Medicine and Surgery, University of Milano-Bicocca, Piazzale Brescia, 20, Milano, Italy.

Antonello Gavazzi (A)

Research Foundation, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1 - 24127 Bergamo, Italy.

Michele Senni (M)

CardioVascular Department, ASST Papa Giovanni XXIII Hospital, Piazza OMS, 1, Bergamo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH